The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response
Abstract
OBJECTIVE: Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD). METHOD: In a large placebo-controlled, double-blind study, patients ages 6-16 with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind conditions. RESULTS: The response rates for both atomoxetine (45%) and methylphenidate (56%) were markedly superior to that for placebo (24%), but the response to osmotically released methylphenidate was superior to that for atomoxetine. Each medication was well tolerated, with completion rates and discontinuations for adverse events not significantly different from those for placebo. Of the 70 subjects who did not respond to methylphenidate, 30 (43%) subsequently responded to atomoxetine. Likewise, 29 (42%) of the 69 patients who did not respond to atomoxetine had previously responded to osmotically released methylphenidate. CONCLUSION: Response was significantly greater with osmotically released methylphenidate than with atomoxetine. One-third of patients who received methylphenidate followed by atomoxetine responded better to one or the other, suggesting that there may be preferential responders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stimulant medications have an effect size of around 1.0 (effect size = [treatment M − control M)/control SD]) for the treatment of ADHD.98”
From Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents (2019) · cites this paper as [98]
In the citing paper
“These shared and distinct substrates may delineate a novel therapeutic target for effective interventions and could account for different therapeutic responses to stimulants and nonstimulants among individuals with ADHD”
From Overlapping and differential neuropharmacological mechanisms of stimulants and nonstimulants for attention-deficit/hyperactivity disorder: A comparative neuroimaging analysis (2024) · cites this paper as Newcorn et al., 2008
In the citing paper
“approximately 56% of ADHD cases may achieve clinical improvement with stimulants, while 45% of cases achieve so with non-stimulants (Mechler et al., 2022; Newcorn et al., 2008).”
From Overlapping and differential neuropharmacological mechanisms of stimulants and nonstimulants for attention-deficit/hyperactivity disorder: A comparative neuroimaging analysis (2024) · cites this paper as Newcorn et al., 2008
In the citing paper
“Lower frequencies of insomnia and higher frequencies of somnolence with atomoxetine than with long-acting stimulants have been reported as TEAEs in randomized, double-blind, parallel-group efficacy studies (Dittmann et al. 2013; Newcorn et al. 2008).”
From Associations of sleep disturbance with ADHD: implications for treatment (2015) · cites this paper as Newcorn et al. 2008
In the citing paper
“In contrast, one large (n = 516), double-blind, placebo-controlled, crossover study found that the proportions of stimulant-naïve children with ADHD who responded to osmotic-release oral system MPH (OROS-MPH) and ATX (64 and 57 %, respectively; effect sizes relative to placebo based on ADHD-RS-IV total score, 1.0 and 0.9) were higher than among those who had previously been treated with a psychost”
In the citing paper
“Nine randomized trials comparing methylphenidate and atomoxetine, with a total of 2762 participants were included.”
In the citing paper
“Two trials excluded participants with previous poor response to methylphenidate, a design feature which would have favoured methylphenidate [27,28].”
In the citing paper
“The outcome in three of these trials favoured atomoxetine suggesting that higher doses of atomoxetine administered twice daily may be more effective.”
Citations
Cites
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
(1998) · Cited by 2,026
Pliszka, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318054e724 · Cited by 1,765
Conners' rating scales-revised : technical manual
Conners, C. K. (1997) · Medical Entomology and Zoology · Cited by 1,004
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Self-citationAttention-Deficit, S. O., & Disorder, H. (2001) · Pediatrics · doi:10.1542/peds.108.4.1033 · Cited by 636
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Self-citationKelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Self-citationSpencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333
Self-citation
Research works printed but not linked: 7
- Jadad AR, 1999, Md
- Kaufman J, 1996, Ryan N: Schedule for Affective Disorders and Schizophrenia for School Aged Children-Present and Lifetime Version (K-SADS-PL)
- World Medical Association, 2000, France
- Gao H, 2006, Scientific Proceedings of the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 201
- Landgraf JM, 1996, Abetz L
- International Conference, 1998, Fed Regist, 63, 49583
- Newcorn JH, 2004, Scientific Proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry, 48
Cited by
Sorted by citations
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
Attention‐Deficit‐Hyperactivity Disorder: An Update
Dopheide, J. A., & Pliszka, S. R. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.6.656 · Cited by 653
A Review of Heterogeneity in Attention Deficit/Hyperactivity Disorder (ADHD)
Luo, Y., Weibman, D., Halperin, J. M., & Li, X. (2019) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2019.00042 · Cited by 394
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Associations of sleep disturbance with ADHD: implications for treatment
Hvolby, A. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-014-0151-0 · Cited by 339
Cortese, S. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.01.009 · Cited by 335
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Evidence-based pharmacological treatment options for ADHD in children and adolescents
Mechler, K., Banaschewski, T., Hohmann, S., & Häge, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107940 · Cited by 293
Stimulant ADHD medication and risk for substance abuse
Chang, Z., Lichtenstein, P., Halldner, L., D'Onofrio, B., Serlachius, E., Fazel, S., Långström, N., & Larsson, H. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12164 · Cited by 225
“…have beneficial short-term effects on symptoms of ADHD (Adler et al., 2009; Banaschewski et al., 2006; Findling, 2008; Findling et al., 2008; Koesters, Becker, Kilian, Fegert, & Weinmann, 2009; Kooij et al., 2010; Newcorn et al., 2008; Svanborg et al., 2009; Young, Sarkis, Qiao, & Wietecha, 2011).”
Mindfulness training for parents and their children with ADHD increases the children's compliance
Singh, N. N., Singh, A. N., Lancioni, G. E., Singh, J., Winton, A. S. W., & Adkins, A. D. (2010) · Journal of Child and Family Studies · doi:10.1007/s10826-009-9272-z · Cited by 215
Storebø, O. J., Krogh, H. B., Ramstad, E., Moreira-Maia, C. R., Holmskov, M., Skoog, M., Nilausen, T. D., Magnusson, F. L., Zwi, M., Gillies, D., et al. (2015) · BMJ · doi:10.1136/bmj.h5203 · Cited by 209
The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety
Heal, D. J., Cheetham, S. C., & Smith, S. L. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.08.020 · Cited by 198
Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats
Baarendse, P. J. J., & Vanderschuren, L. J. M. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2576-x · Cited by 169
Schwartz, S., & Correll, C. U. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.005 · Cited by 166
Jonsson, U., Alaie, I., Löfgren Wilteus, A., Zander, E., Marschik, P. B., Coghill, D., & Bölte, S. (2017) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12645 · Cited by 164
Berridge, C. W., & Devilbiss, D. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.023 · Cited by 160
Enhancing ADHD Medication Adherence: Challenges and Opportunities
Charach, A., & Fernandez, R. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0371-6 · Cited by 174
Hanwella, R., Senanayake, M., & de Silva, V. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-176 · Cited by 137
Coghill, D., Banaschewski, T., Soutullo, C. A., Cottingham, M. G., & Zuddas, A. (2017) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-017-0986-y · Cited by 136
Schulz, K. P., Fan, J., Bédard, A.-C. V., Clerkin, S. M., Ivanov, I., Tang, C. Y., Halperin, J. M., & Newcorn, J. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2053 · Cited by 114
Self-citationReed, V. A., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., Coghill, D. R., Kryzhanovskaya, L. A., & Savill, N. C. (2016) · CNS Drugs · doi:10.1007/s40263-016-0349-0 · Cited by 113
An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults
Wilens, T. E., Morrison, N. R., & Prince, J. B. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.137 · Cited by 117
Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges
Dunn, D., Williams, A. E., Giust, J., & Kronenberger, W. G. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s81549 · Cited by 116
Faraone, S. V. (2009) · PubMed · Cited by 107
Cohen, S. C., Mulqueen, J. M., Ferracioli-Oda, E., Stuckelman, Z. D., Coughlin, C. G., Leckman, J. F., & Bloch, M. H. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2015.06.011 · Cited by 105
van de Loo-Neus, G. H. H., Rommelse, N., & Buitelaar, J. K. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.03.008 · Cited by 98
Marquand, A. F., Simoni, S. D., O’Daly, O., Williams, S., Mourão-Miranda, J., & Mehta, M. A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.9 · Cited by 96
Stein, M. A., Waldman, I. D., Charney, E., Aryal, S., Sable, C., Gruber, R., & Newcorn, J. H. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2011.0018 · Cited by 93
Self-citationNewcorn, J. H., Sutton, V. K., Weiss, M. D., & Sumner, C. R. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31819c55b2 · Cited by 92
Self-citationDittmann, R. W., Cardo, E., Nagy, P., Anderson, C. S., Bloomfield, R., Caballero, B., Higgins, N., Hodgkins, P., Lyne, A., Civil, R., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0104-8 · Cited by 88
Cunill, R., Cervelló, X. C., Tobı́as, A., & Capellà, D. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4099-3 · Cited by 91
Coughlin, C. G., Cohen, S. C., Mulqueen, J. M., Ferracioli-Oda, E., Stuckelman, Z. D., & Bloch, M. H. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0075 · Cited by 86
Childress, A. C., & Sallee, F. R. (2014) · CNS Drugs · doi:10.1007/s40263-013-0130-6 · Cited by 89
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Storm, M. R. O., Ribeiro, J. P., Skoog, M., Groth, C., Edemann-Callesen, H., Schaug, J. P., Rasmussen, P. D., Huus, C.-M. L., Zwi, M., et al. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub3 · Cited by 118
Stuhec, M., Munda, B., Svab, V., & Locatelli, I. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.03.006 · Cited by 83
Matthijssen, A. M., Dietrich, A., Bierens, M., Deters, R. K., van de Loo-Neus, G. H. H., van den Hoofdakker, B. J., Buitelaar, J. K., & Hoekstra, P. J. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18111296 · Cited by 90
Buitelaar, J. K., & Medori, R. (2009) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0056-1 · Cited by 80
Bupropion for attention deficit hyperactivity disorder (ADHD) in adults.
Verbeeck, W., Bekkering, G., den Noortgate, W. V., & Kramers, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009504.pub2 · Cited by 73
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder in Adolescents
Childress, A. C., & Berry, S. A. (2012) · Drugs · doi:10.2165/11599580-000000000-00000 · Cited by 77
Clemow, D. B., & Bushe, C. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115602489 · Cited by 79
Yildiz, O., Şişmanlar, Ş. G., Memik, N. Ç., Karakaya, İ., & Ağaoğlu, B. (2010) · Child Psychiatry & Human Development · doi:10.1007/s10578-010-0212-3 · Cited by 78
Bushe, C., & Savill, N. C. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113478475 · Cited by 75
Marquand, A. F., O’Daly, O., Simoni, S. D., Alsop, D. C., Maguire, R. P., Williams, S., Zelaya, F. O., & Mehta, M. A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.058 · Cited by 70
Weiss, M. D., Gibbins, C., Goodman, D. W., Hodgkins, P., Landgraf, J. M., & Faraone, S. V. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04709pur · Cited by 74
Ching, C., Eslick, G. D., & Poulton, A. S. (2019) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2019.0905 · Cited by 70
Emilsson, M., Gustafsson, P. A., Öhnström, G., & Marteinsdóttir, Í. (2016) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-016-0919-1 · Cited by 79
Neurodevelopmental Behavioral and Cognitive Disorders
Jeste, S. (2015) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000466661.89908.3c · Cited by 71
Sluggish cognitive tempo, processing speed, and internalizing symptoms: the moderating effect of age
Jacobson, L. A., Geist, M., & Mahone, E. M. (2018) · Journal of Abnormal Child Psychology · doi:10.1007/s10802-017-0281-x · Cited by 67
Fu, D., Wu, D.-D., Guo, H.-L., Hu, Y.-H., Xia, Y., Ji, X., Fang, W.-R., Li, Y.-M., Xu, J., Chen, F., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780921 · Cited by 66
Core ADHD Symptom Improvement With Atomoxetine Versus Methylphenidate
Hazell, P., Kohn, M. R., Dickson, R. A., Walton, R., Granger, R. E., & van Wyk, G. W. (2010) · Journal of Attention Disorders · doi:10.1177/1087054710379737 · Cited by 65
Bymaster, F. P., Gołembiowska, K., Kowalska, M., Choi, Y. K., & Tarazi, F. I. (2012) · Synapse · doi:10.1002/syn.21538 · Cited by 65
Kratochvil, C. J., Milton, D. R., Vaughan, B. S., & Greenhill, L. L. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-25 · Cited by 64
Self-citationMontoya, A., Amaia Hervas, G., Cardo, E., Artigas-Pallarés, J., Mardomingo, M. J., Alda, J. A., Gastaminza, X., García-Polavieja, M. J., Gilaberte, I., & Escobar, R. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903316152 · Cited by 64
Pharmacotherapy for Child and Adolescent Attention-deficit Hyperactivity Disorder
Kaplan, G., & Newcorn, J. H. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.10.009 · Cited by 63
Self-citationBedard, A., Stein, M. A., Halperin, J. M., Krone, B., Rajwan, E., & Newcorn, J. H. (2014) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12272 · Cited by 66
Self-citationAttention-Deficit Hyperactivity Disorder
MAY, D. E., & Kratochvil, C. J. (2009) · Drugs · doi:10.2165/11530540-000000000-00000 · Cited by 62
Self-citationBarragán, E., Breuer, D., & Döpfner, M. (2014) · Journal of Attention Disorders · doi:10.1177/1087054713518239 · Cited by 70
A critical appraisal of atomoxetine in the management of ADHD
Childress, A. C. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s59270 · Cited by 65
Padilha, S. C., Virtuoso, S., Tonin, F. S., Borba, H. H. L., & Pontarolo, R. (2018) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1125-0 · Cited by 64
Yang, L., Cao, Q., Shuai, L., Li, H., Chan, R. C. K., & Wang, Y. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001490 · Cited by 63
GELLER, D. A., McCarthy, K., Mancuso, E., Gendron, C., & GELLER, D. A. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s3896 · Cited by 61
Nagashima, M., Monden, Y., Dan, I., Dan, H., Tsuzuki, D., Mizutani, T., Kyutoku, Y., Gunji, Y., Hirano, D., Taniguchi, T., et al. (2014) · NeuroImage Clinical · doi:10.1016/j.nicl.2014.09.001 · Cited by 63
Treuer, T., Gau, S. S.-F., Méndez, L., Montgomery, W., Monk, J. A., Altin, M., Wu, S., Lin, C. C. H., & Dueñas, H. J. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0093 · Cited by 58
Safety and Tolerability of Atomoxetine Over 3 to 4 Years in Children and Adolescents With ADHD
Donnelly, C. L., Bangs, M. E., Trzepacz, P. T., Jin, L., Zhang, S., Witte, M. M., Ball, S. G., & Spencer, T. J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318193060e · Cited by 59
Ishii‐Takahashi, A., Takizawa, R., Nishimura, Y., Kawakubo, Y., Kuwabara, H., Matsubayashi, J., Hamada, K., Okuhata, S., Yahata, N., Igarashi, T., et al. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.10.002 · Cited by 58
Ramoz, N., Boni, C., Downing, A. M., Close, S. L., Peters, S. L., Prokop, A. M., Allen, A. J., Hamon, M., Purper‐Ouakil, D., & Gorwood, P. A. P. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.39 · Cited by 57
Self-citationPozzi, M., Carnovale, C., Peeters, G. G. A. M., Gentili, M., Antoniazzi, S., Radice, S., Clementi, E., & Nobile, M. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.05.021 · Cited by 56
Atomoxetine facilitates attentional set shifting in adolescent rats
Cain, R. E., Wasserman, M. C., Waterhouse, B. D., & McGaughy, J. A. (2011) · Developmental Cognitive Neuroscience · doi:10.1016/j.dcn.2011.04.003 · Cited by 55
Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
Huß, M., Chen, W., & Ludolph, A. G. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0336-0 · Cited by 60
Savill, N. C., Buitelaar, J. K., Anand, E., Day, K. A., Treuer, T., Upadhyaya, H. P., & Coghill, D. (2015) · CNS Drugs · doi:10.1007/s40263-014-0224-9 · Cited by 59
ADHD: Current and Future Therapeutics
Heal, D. J., Smith, S. L., & Findling, R. L. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_125 · Cited by 55
Ruggiero, S., Clavenna, A., Reale, L., Capuano, A., Rossi, F., & Bonati, M. R. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.08.001 · Cited by 55
Nasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Chowdhry, F. A., Busse, G. D., Melyan, Z., Cutler, A. J., Findling, R. L., et al. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.01.027 · Cited by 56
Treceño, C., Arias, L. H. M., Saínz, M., Salado, I., Ortega, P. G., Velasco, V., Jimeno, N., Escudero, A., Velasco, A., & Carvajal, A. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2348 · Cited by 47
Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder
Huang, Y., & Tsai, M.-H. (2011) · CNS Drugs · doi:10.2165/11589380-000000000-00000 · Cited by 54
Smith, A., Cubillo, A., Barrett, N., Giampietro, V., Simmons, A., Brammer, M., & Rubia, K. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.030 · Cited by 53
Current issues around the pharmacotherapy of ADHD in children and adults
Meijer, W. M., Faber, A., van den Ban, E. F., & Tobi, H. (2009) · Pharmacy World & Science · doi:10.1007/s11096-009-9302-3 · Cited by 55
Sigurdardottir, H. L., Kranz, G. S., Rami‐Mark, C., James, G. M., Vanicek, T., Gryglewski, G., Kautzky, A., Hienert, M., Traub‐Weidinger, T., Mitterhauser, M., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23071 · Cited by 51
Bangs, M. E., Wietecha, L. A., Wang, S., Buchanan, A. S., & Kelsey, D. K. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0005 · Cited by 52
Alkam, T., Mamiya, T., Kimura, N., Yoshida, A., Kihara, D., Tsunoda, Y., Aoyama, Y., Hiramatsu, M., Kim, H.-C., & Nabeshima, T. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4591-z · Cited by 50
Dickson, R. A., Maki, E., Gibbins, C., Gutkin, S. W., Turgay, A., & Weiss, M. D. (2011) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-5-14 · Cited by 52
Kratz, O., Studer, P., Baack, J., Malcherek, S., Erbe, K., Moll, G. H., & Heinrich, H. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.12.008 · Cited by 55
Newcorn, J. H., Nagy, P., Childress, A. C., Frick, G., Yan, B., & Pliszka, S. (2017) · CNS Drugs · doi:10.1007/s40263-017-0468-2 · Cited by 50
Self-citationUpdate on atomoxetine in the treatment of attention-deficit/hyperactivity disorder
Vaughan, B. S., Fegert, J. M., & Kratochvil, C. J. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902762873 · Cited by 49
Self-citationBellato, A., Perrott, N. J., Marzulli, L., Parlatini, V., Coghill, D., & Cortese, S. (2024) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2024.05.023 · Cited by 54
ADHD in children and youth: Part 2—Treatment
Feldman, M. E., Charach, A., & Bélanger, S. A. (2018) · Paediatrics & Child Health · doi:10.1093/pch/pxy113 · Cited by 60
Aagaard, L., & Hansen, E. H. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s26403 · Cited by 51
Pharmacotherapy of Pediatric Attention-Deficit/Hyperactivity Disorder
Vaughan, B., & Kratochvil, C. J. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.005 · Cited by 46
Self-citationNasser, A. F., Liranso, T., Adewole, T., Fry, N., Hull, J. T., Busse, G. D., Chowdhry, F. A., Cutler, A. J., Jones, N. J., Findling, R. L., et al. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001404 · Cited by 47
Dittmann, R., Schacht, A., Helsberg, K., Schneider-Fresenius, C., Lehmann, M., Lehmkuhl, G., & Wehmeier, P. M. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0111 · Cited by 45
Newcorn, J. H., Sutton, V. K., Zhang, S., Wilens, T. E., Kratochvil, C. J., Emslie, G. J., D’Souza, D. N., Schuh, L. M., & Allen, A. J. (2009) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3181bc730d · Cited by 47
Self-citationFaraone, S. V., McBurnett, K., Sallee, F. R., Steeber, J., & López, F. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.09.005 · Cited by 44
Chou, T.-L., Chia, S., Shang, C.-Y., & Gau, S. S.-F. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.024 · Cited by 44
Hammerness, P. G., Georgiopoulos, A. M., Doyle, R., Utzinger, L. M., Schillinger, M., Martelon, M., Brodziak, K., Biederman, J., & Wilens, T. E. (2009) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2008.0126 · Cited by 43
Roskell, N. S., Setyawan, J., Zimovetz, E. A., & Hodgkins, P. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.904772 · Cited by 42
An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD
Ni, H., Lin, Y., Gau, S. S., Huang, H., & Yang, L.-K. (2013) · Journal of Attention Disorders · doi:10.1177/1087054713476549 · Cited by 43
Drug therapy of attention deficit hyperactivity disorder: Current trends
Sousa, A. D., & Kalra, G. (2012) · Mens Sana monographs · doi:10.4103/0973-1229.87261 · Cited by 46
Hutchison, S. L., GHUMAN, J. K., Ghuman, H. S., Karpov, I. O., & Schuster, J. M. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316647686 · Cited by 42
Metadata
- Authors
- Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group
- Affiliations
- Mount Sinai Hospital (US)
- Venue
- American Journal of Psychiatry
- Published
- 2008-06
- Volume
- 165
- Issue
- 6
- Pages
- 721-730
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2130386846
- Cited by
- 336
- References
- 23
- Citations by year
- 2026: 3 · 2025: 10 · 2024: 10 · 2023: 11 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 14 · 2018: 9 · 2017: 21 · 2016: 20 · 2015: 33 · 2014: 32 · 2013: 20 · 2012: 30
- FWCI
- 22.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, non-stimulant medication, norepinephrine reuptake inhibitors, treatment response, differential drug response, children and adolescents, ADHD Rating Scale
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Central Nervous System Stimulants, Child, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Methylphenidate, Personality Assessment, Propylamines, Treatment Outcome, Cross-Over Studies, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
